Company Website

Contact Information:

Melissa Wilmer
Senior Hematology Specialist - Leukemia
Cell:  319-830-5681
Office:  319-270-9811
mwilmer@amgen.com

Jennifer DeGrave, BSN, RN, OCN
Sr. Clinical Hematology Specialist-Multiple Myeloma
Cell: 612.210.7216
jdegrave@amgen.com

Virtual Exhibit Hall Home

Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.

THE HUNT FOR NEW CHECKPOINT INHIBITORS

Drugs that release the brakes on immune cells have helped many cancer patients, but not enough. Amgen is using human genetics and cutting-edge biology to search for new checkpoint targets that will work in more types of cancer and more patients.
In the quest to make cancer a curable disease, a lot is riding on advances in the field of immuno-oncology. Medicines that spur an immune attack against tumor cells are helping patients to live longer and even become disease-free in some cases.

“Up to about 20 years ago, the word cure was almost forbidden in oncology,” said Flavius Martin, vice president for Oncology Research at Amgen. “In the last 10 years, immunotherapy has given us hope.”

Extending that hope to more patients has become a major focus of cancer research. “We still have a long way to go,” said Ray Deshaies, Amgen’s senior vice president for Research. “So far, immunotherapy only works in a minority of cancers. Even in those cancers where it does work, you typically see a striking remission in only about one-third of the patients treated. But I’m very optimistic about the future and in particular about the work that Amgen is doing now.”

BLINCYTO® BLAST Study 

BLINCYTO® Tower Study 

BLINCYTO® Pediatric Data 

BLINCYTO® Package Insert

KYPROLIS® Clinical Data